ArticleJournal of cosmetic dermatology2025
Integrating VYC-12L With Energy-Based Devices for Skin-Quality Improvement: Global Expert Considerations for Safe and Effective Outcomes.
Article in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrating VYC-12L With Energy-Based Devices for Skin-Quality Improvement: Global Expert Considerations for Safe and Effective Outcomes.Journal of cosmetic dermatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundEnergy-based devices (EBDs) and injectable hyaluronic acid gels, such as VYC-12L, are each effective treatment modalities for improving skin quality.
objectivesTo assess the rationale and potential benefits of adding VYC-12L to EBD treatments, and consider how they can be practically integrated into a single treatment plan.
methodsEight clinicians with various specialties and extensive experience of these modalities completed a written questionnaire and were individually interviewed. Their collective clinical expertise and experience form the basis of this guidance.
resultsUsing both VYC-12L and EBDs within a single treatment plan offers many potential benefits for improving skin quality-based on mechanistic synergies and complementary abilities to address different attributes and multiple anatomical layers. Careful consideration should be given to appropriate sequencing. VYC-12L and non-ablative EBDs can be used on the same day, but treatment fields must be appropriately managed and aseptic technique rigorously upheld. When administering VYC-12L, maintaining the correct injection depth is essential to positive outcomes. Practitioners should undertake appropriate training and select the injection tools that optimize control.
conclusionsMultimodal treatment using VYC-12L and EBDs together can provide a more comprehensive, tailored approach to skin-quality improvement, delivering high levels of patient satisfaction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.